Allogene Therapeutics, Inc. (ALLO)

Market Cap	965.36M +183.0%
Revenue (ttm)	n/a
Net Income	-190.89M
EPS	-0.87
Shares Out	243.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,298,087
Open	4.080
Previous Close	2.720
Day's Range	3.550 - 4.100
52-Week Range	0.862 - 4.100
Beta	0.54
Analysts	Buy
Price Target	8.40 (+112.12%)
Earnings Date	May 12, 2026

About ALLO

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 11, 2018
• Employees: 152
• Stock Exchange: NASDAQ
• Ticker Symbol: ALLO
• Website: https://allogene.com

Analyst Summary

According to 11 analysts, the average rating for ALLO stock is "Buy." The 12-month stock price target is $8.4, which is an increase of 112.12% from the latest price.

Price Target

$8.4

(112.12% upside)

Analyst Consensus: Buy